Propanc Biopharma (NASDAQ:PPCB) Releases Quarterly Earnings Results

Propanc Biopharma (NASDAQ:PPCB) posted its quarterly earnings data on Friday. The company reported $6.13 earnings per share for the quarter, FiscalAI reports.

Propanc Biopharma Trading Up 4.7%

PPCB opened at $0.63 on Friday. The stock has a market capitalization of $1.44 million, a P/E ratio of -0.03 and a beta of 3.52. The stock has a 50-day moving average price of $1.08 and a 200-day moving average price of $1.84. Propanc Biopharma has a 12-month low of $0.56 and a 12-month high of $52.50.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Propanc Biopharma declared that its board has initiated a share repurchase program on Thursday, June 11th that permits the company to repurchase $5.00 million in shares. This repurchase authorization permits the company to repurchase up to 162.3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s management believes its shares are undervalued.

Propanc Biopharma Company Profile

Propanc Biopharma, Inc is a biotechnology company focused on developing novel treatments for solid tumors. The company’s research centers on the use of proenzymes—precursors to digestive enzymes—as a potential therapeutic approach for targeting cancer cells and limiting tumor growth, recurrence and metastasis.

Propanc’s lead product candidate is PRP, an investigational proenzyme therapy being developed primarily for cancers with a high risk of recurrence, including pancreatic, ovarian and colorectal cancers.